Related Experiment Video
Updated: Sep 13, 2025

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
Fatal Toxic Megacolon Following Nivolumab and Ipilimumab Therapy in Metastatic Melanoma: A Case Report
Hibiki Fujiwara1, Takuya Maeda1, Takehiko Katsurada2
1Department of Dermatology, Hokkaido University, Sapporo, JPN.
Abstract:
In this case report, we describe a 76-year-old man with advanced malignant melanoma who developed severe colitis and toxic megacolon following nivolumab plus ipilimumab therapy. Despite treatment with prednisolone, infliximab, and vedolizumab, the patient's condition deteriorated, resulting in hypoalbuminemia and unfeasibility of surgical intervention. Elevated C-reactive protein (CRP) levels served as a critical diagnostic clue, prompting abdominal radiography, which subsequently confirmed the diagnosis of toxic megacolon. This case highlights a rare but life-threatening complication of immune checkpoint inhibitors and underscores the challenges in managing refractory immune-related colitis. Given the increasing use of immune checkpoint inhibitors in clinical practice, this report will be of significant interest to readers by emphasizing the importance of timely recognition, CRP monitoring, and intervention to prevent fatal outcomes in similar cases.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Tumor Immunotherapy
Drugs for Treatment of Ulcerative Colitis in IBD

